After signing up, you'll start to receive regular news updates from us.
Interleukin Expands DNA Analysis Laboratory Operations
Complete the form below to unlock access to ALL audio articles.
Interleukin Genetics has announced the completion of the expansion and upgrade of its Laboratory Operations. This will allow the company to meet the demand for its DNA risk assessment tests.
Interleukin has added equipment and staff to enable the company to improve turnaround time for test results and to increase efficiencies and overall capacity for future growth.
"Interleukin Genetics has added the throughput capacity to meet the demand for our new DNA based cardiovascular and nutritional wellness risk assessment tests," commented Ken Kornman, DDS, PhD, CEO of Interleukin Genetics.
"We are pleased that the early sales of our current DNA risk assessment tests exceeded expectations."
"These laboratory enhancements significantly improve test turnaround time to meet the needs of our customers," continued Dr. Kornman.
